HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1746-1596
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population ; volume:8 ; number:1 ; day:9 ; month:5 ; year:2013 ; pages:1-7 ; date:12.2013
Diagnostic pathology ; 8, Heft 1 (9.5.2013), 1-7, 12.2013
- Creator
-
Shan, Ling
- Contributor
-
Ying, Jianming
Lu, Ning
SpringerLink (Online service)
- DOI
-
10.1186/1746-1596-8-76
- URN
-
urn:nbn:de:1111-2016080742924
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shan, Ling
- Ying, Jianming
- Lu, Ning
- SpringerLink (Online service)
Other Objects (12)
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma : Past, present and future
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma